Internal medicine (Tokyo, Japan)
Cure8 research brief
Why This Matters
Atypical colitis occurring after rituximab is relevant to patients and clinicians because it may mimic Crohn's disease and require different management; recognizing drug‑associated colitis could affect diagnostic workup and treatment choices.
Who Should Pay Attention
Clinicians (gastroenterologists, transplant physicians, hematologists), researchers studying drug‑induced colitis, and patients receiving rituximab or other B‑cell–depleting therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
A man in his 40s with chronic active EBV infection received rituximab after PTLD and later developed longitudinal ulcers of the colon with endoscopic appearance resembling Crohn's colitis; other causes (GVHD, recurrent PTLD, CMV enteritis, vasculitis) were reportedly excluded.
The authors describe clinical and endoscopic remission after treatment with an infliximab biosimilar. The report frames rituximab-associated Crohn's‑like colitis as a rare but important complication.
The account is a single case report based on an abstract-level summary, so it cannot establish how often this happens or prove causation between rituximab and colitis. Clinicians and patients should consider this as hypothesis‑generating and discuss any new gastrointestinal symptoms after rituximab with their care team.
Keep In Mind
This classification and brief are based on an abstract-level case report. Single-case reports can highlight possible adverse events but cannot determine frequency or causation. The abstract reports exclusion of common alternative diagnoses and response to anti‑TNF therapy, but details are limited in the supplied text.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationInternal medicine (Tokyo, Japan)
AuthorsHigaki K, Okabe M, Shimizu R +8 more
Study typeIm, journal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedSep 29, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Ustekinumab-induced Focal Segmental... : Journal of Nature and Science of Medicine - Ovid
This case suggests ustekinumab — a commonly used biologic for Crohn’s disease — might rarely be associated with kidney injury (FSGS). Patients and clinicians should be aware of new or worsening edema, proteinuria, or...
Infliximab-Associated IgA Vasculitis Masquerading as Crohn's Disease Relapse: Leukocytoclastic Vasculitis Confirmed on Duodenal Biopsy - A Case Report.
IgA vasculitis can be a rare adverse effect of anti-TNF therapy like infliximab and may mimic Crohn’s relapse, so recognizing it can prevent incorrect escalation of IBD treatment.
Tracheobronchial Wall Thickening in a Patient With Inflammatory Bowel Disease.
A person with Crohn disease on multiple immunosuppressive drugs was reported to have tracheobronchial wall thickening, an extraintestinal finding that could reflect infection or inflammation. This may be relevant for...